JPRN-UMIN000004993已完成未知
Clinical research of the prediction of clinical outcome in patients with metastatic colorectal cancer treated with cetuximab - IBACET study
Cancer Chemotherapy Group in Ibaraki Cancer Clinical Epidemiology Study0 个研究点目标入组 50 人开始时间: 2011年2月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
The 9th Annual Meeting of Japanese Society of Medical Oncology KRAS and BRAF mutations as predictive/prognostic factors in patients with metastatic colorectal cancer treated with cetuximab
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Unable to assess the efficacy of cetuximab treatment 2) Other conditions not suitable for this study
研究者
相似试验
已完成
不适用
Comparison of KRAS/BRAF Mutational Status With Conventional Techniques and Plasma Samples AnalysisColorectal CancerNCT02784639Institut du Cancer de Montpellier - Val d'Aurelle115
已完成
不适用
Multitarget Stool FIT-DNA Study for Colorectal Cancer Early Screening in ChinaAdenomatous PolypsAdenomaAdvanced AdenomaColorectal CancerNCT04287335Zhejiang University4,758
尚未招募
不适用
Prevalence of two mutations (KRAS and BRAF) in patients diagnosed with Colorectal Cancer.CTRI/2013/09/004023Dr Prachi S Patil200
已完成
不适用
A clinical study of relevance to KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerColorectal cancerJPRN-UMIN000013154Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences20
已完成
不适用
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRIColorectal CancerNCT03698253Kaohsiung Medical University Chung-Ho Memorial Hospital41